Literature DB >> 17379434

Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer.

Marketa Skala1, Tara Rosewall, Laura Dawson, Lorella Divanbeigi, Gina Lockwood, Christopher Thomas, Juanita Crook, Peter Chung, Padraig Warde, Charles Catton.   

Abstract

PURPOSE: The aims of this study were to determine the incidence of patient-assessed late toxicity after high-dose, image-guided radiation therapy in a cohort of men with prostate cancer; and to correlate toxicity with conventional dosimetric parameters and rectal and bladder dose-volume histograms (DVH) reduced using principal component analysis. METHODS AND MATERIALS: Toxicity questionnaires were sent to 690 men treated for localized prostate cancer to 75.6 Gy or 79.8 Gy using three-dimensional conformal radiation therapy (3DCRT) or intensity-modulated radiation therapy (IMRT) between 1997 and 2003 at the Princess Margaret Hospital. Toxicity was graded according to the modified Radiation Therapy Oncology Group (RTOG)-late effects normal tissue (LENT) scoring system. Late rectal and bladder toxicity scores were dichotomized as < Grade 2 and > or = Grade 2, and correlated with dosimetric parameters and with the first three principal components of rectal and bladder DVHs.
RESULTS: In all, 63% of the patients completed the questionnaire. At a median follow-up of 37 months, the incidence of late rectal toxicity RTOG Grades 1, 2, and 3 was 25.2%, 2.5%, and 0.7% respectively. The incidence of late urinary toxicity RTOG Grade 1, 2, and 3 was 16.5%, 8.8%, and 0.9% respectively. Maintenance of erectile function sufficient for intercourse was reported in 68%. No dosimetric parameter analyzed, including principal component analysis reduction of DVHs, correlated with late toxicity.
CONCLUSIONS: Postal questionnaire was effective for collection of patient-assessed late toxicity data. The incidence of late toxicity was low, with a lack of correlation to dosimetric parameters. We attribute this to the use of conformal techniques and daily image guidance.

Entities:  

Mesh:

Year:  2007        PMID: 17379434     DOI: 10.1016/j.ijrobp.2006.12.064

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data.

Authors:  Yun Liang; Karen Messer; Brent S Rose; John H Lewis; Steve B Jiang; Catheryn M Yashar; Arno J Mundt; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-14       Impact factor: 7.038

2.  Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.

Authors:  Michael Sia; George Rodrigues; Cynthia Menard; Andrew Bayley; Robert Bristow; Peter Chung; Mary Gospodarowicz; Michael Milosevic; Padraig Warde; Charles Catton
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy.

Authors:  Antonio José Conde-Moreno; Carlos Ferrer-Albiach; Mercedes Zabaleta-Meri; Xavi J Juan-Senabre; Agustín Santos-Serra
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 4.  Radiation dose-volume effects and the penile bulb.

Authors:  Mack Roach; Jiho Nam; Giovanna Gagliardi; Issam El Naqa; Joseph O Deasy; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

5.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

6.  Parametrized rectal dose and associations with late toxicity in prostate cancer radiotherapy.

Authors:  Lynsey J Hamlett; Andrew J McPartlin; Edward J Maile; Gareth Webster; Ric Swindell; Carl G Rowbottom; Ananya Choudhury; Adam H Aitkenhead
Journal:  Br J Radiol       Date:  2015-08-06       Impact factor: 3.039

7.  Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).

Authors:  Isabel Syndikus; Rachel C Morgan; Matthew R Sydes; John D Graham; David P Dearnaley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

8.  Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer.

Authors:  Jeroen Houben; Gill McColl; Johannes Ham Kaanders; Robert J Smeenk
Journal:  Clin Transl Radiat Oncol       Date:  2021-05-21

9.  Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.

Authors:  Pirus Ghadjar; Jacqueline Vock; Daniel Vetterli; Peter Manser; Roland Bigler; Jan Tille; Axel Madlung; Frank Behrensmeier; Roberto Mini; Daniel M Aebersold
Journal:  Radiat Oncol       Date:  2008-10-20       Impact factor: 3.481

10.  High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.

Authors:  Irene M Lips; Homan Dehnad; Carla H van Gils; Arto E Boeken Kruger; Uulke A van der Heide; Marco van Vulpen
Journal:  Radiat Oncol       Date:  2008-05-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.